CLL Has Many Effective Drugs, And Costs Are Expected to Rise

February 1

Among the different forms of leukemia, chronic lymphocytic leukemia (CLL) is one of the most common in adults. The FDA has approved multiple treatments for the condition, making it a potential target of value-based contracts — assuming manufacturers would be amenable to such deals.

According to the American Cancer Society, about one-quarter of new leukemia cases are CLL, which is one of the more than 60 subtypes of non-Hodgkin lymphoma.

0 Comments

Radar on Specialty Pharmacy

Angela Maas

Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

Many Payers Will Parity Prefer Xtandi, Chemotherapy in mHSPC February 1, 2020

Multiple Myeloma, Multiple Sclerosis, Breast Cancer Drugs Are Among Those Going Off Patent in 2020 February 1, 2020